UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications

被引：27

作者：

Chang, J-C. ^{[2
]}

Liu, E. H. ^{[3
,4
]}

Lee, C-N. ^{[5
]}

Lin, Y-C. ^{[6
]}

Yu, M-C. ^{[3
]}

Bai, K-J ^{[3
]}

Chen, H-Y. ^{[1
,2
]}

机构：

[1] Taipei Med Univ, Sch Pharm, Taipei 116, Taiwan

[2] Taipei Med Univ, Dept Pharm, Wan Fang Hosp, Taipei 116, Taiwan

[3] Taipei Med Univ, Dept Internal Med, Wan Fang Hosp, Taipei 116, Taiwan

[4] Taipei Med Univ, Grad Inst Clin Med, Taipei 116, Taiwan

[5] Taipei Med Univ, Dept Internal Med, Shuang Ho Hosp, Taipei 116, Taiwan

[6] Kaohsiung Med Univ, Sch Pharm, Kaohsiung, Taiwan

来源：

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE | 2012年 / 16卷 / 03期

关键词：

UGT1A1; NAT2; ATDH; anti-tuberculosis drug-induced hepatotoxicity; UDP-GLUCURONOSYLTRANSFERASE; GILBERTS-SYNDROME; BILIRUBIN; GENE; TAIWANESE;

D O I：

10.5588/ijtld.11.0404

中图分类号：

R51 [传染病];

学科分类号：

100201 [内科学];

摘要：

First-line drug treatment for tuberculosis (TB) is frequently associated with liver toxicity. The goal of this study was to examine the association between UDP-glucuronosyl-transferase 1A1 (UGT1A1) genetic variations and anti-tuberculosis drug-induced hepatotoxicity (ATDH). A total of 98 patients, including 17 patients with ATDH, were enrolled; compound UGT1A1*27 and UGT1A1*28 were associated with an increased risk for developing ATDH after adjusting for age (OR 13.859; 95%CI 1.085-177.056). These findings require confirmation. However, screening for genetic variations prior to TB treatment may reduce the incidence of ATDH and improve treatment adherence.

引用

页码：376 / 378

页数：3

共 12 条

[1]

Ando Y, 2000, CANCER RES, V60, P6921

[2]

BENICHOU C, 1990, J HEPATOL, V11, P272

[3]

Inherited disorders of bilirubin metabolism [J].

Bosma, PJ .

JOURNAL OF HEPATOLOGY, 2003, 38 (01) :107-117

[4]

A COMPARISON OF LINKAGE DISEQUILIBRIUM MEASURES FOR FINE-SCALE MAPPING [J].

DEVLIN, B ;

RISCH, N .

GENOMICS, 1995, 29 (02) :311-322

[5]

Huang Ching-Shan, 2005, Pharmacogenet Genomics, V15, P43, DOI 10.1097/01213011-200501000-00007

[6]

Variations of the bilirubin uridine-diphosyphoglucuronosyl transferase 1A1 gene in healthy Taiwanese [J].

Huang, CS ;

Luo, GA ;

Huang, MJ ;

Yu, SC ;

Yang, SS .

PHARMACOGENETICS, 2000, 10 (06) :539-544

[7]

Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis [J].

Huang, YS ;

Chern, HD ;

Su, WJ ;

Wu, JC ;

Lai, SL ;

Yang, SY ;

Chang, FY ;

Lee, SD .

HEPATOLOGY, 2002, 35 (04) :883-889

[8]

GILBERTS-SYNDROME IS CAUSED BY A HETEROZYGOUS MISSENSE MUTATION IN THE GENE FOR BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE [J].

KOIWAI, O ;

NISHIZAWA, M ;

HASADA, K ;

AONO, S ;

ADACHI, Y ;

MAMIYA, N ;

SATO, H .

HUMAN MOLECULAR GENETICS, 1995, 4 (07) :1183-1186

[9]

NAT2*7 allele is a potential risk factor for adult brain tumors in Taiwanese population [J].

Liu, H. Eugene ;

Hsiao, Pei-Yu ;

Lee, Ching-Chen ;

Lee, Jen-Ai ;

Chen, Hsiang-Yin .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (03) :661-665

[10]

UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer [J].

Sai, K ;

Saeki, M ;

Saito, Y ;

Ozawa, S ;

Katori, N ;

Jinno, H ;

Hasegawa, R ;

Kaniwa, N ;

Sawada, J ;

Komamura, K ;

Ueno, K ;

Kamakura, S ;

Kitakaze, M ;

Kitamura, Y ;

Kamatani, N ;

Minami, H ;

Ohtsu, A ;

Shirao, K ;

Yoshida, T ;

Saijo, N .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (06) :501-515

← 1 2 →